Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocravimod adjunctive therapy after allogeneic HSCT in AML
2021-002864-36Phase 2Active
- Sponsor
- Priothera
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Mocravimod + allogeneic HSCT with Placebo + allogeneic HSCT (2 arms). Primary endpoint: Refractory GVHD-free, relapse-free survival. Started Sep 2021; status: active.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-002864-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002864-36.